Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS)

References

• Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 2014;122:231-66
   PubMedGoogle Scholar
• Trojano M, Paolicelli D, Tortorella C, et al. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol Clin 2011;29:309-21
   PubMed Web of Science ®Google Scholar
• El-Salem K, Al-Shimmery E, Horany K, et al. Multiple sclerosis in Jordan: a clinical and epidemiological study. J Neurol 2006;253:1210-16
   PubMed Web of Science ®Google Scholar
• Al-Hashel J, Besterman AD, Wolfson C. The prevalence of multiple sclerosis in the Middle East. Neuroepidemiology 2008;31:129-37
   PubMed Web of Science ®Google Scholar
• Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci 2011;121:393-8
   PubMed Web of Science ®Google Scholar
• Deleu D, Mir D, Al Tabouki A, et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler 2013;19:816-19
   PubMed Web of Science ®Google Scholar
• Alroughani R, Ahmed SF, Behbahani R, et al. Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. Mult Scler 2014;20:543-7
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Izadi S, Nikseresht A, et al. Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 2014;72:370-4
   PubMed Web of Science ®Google Scholar
• Jabbour RA, Kanj SS, Sawaya RA, et al. Toxocara canis myelitis: clinical features, magnetic resonance imaging (MRI) findings, and treatment outcome in 17 patients. Medicine (Baltimore) 2011;90:337-43
   PubMed Web of Science ®Google Scholar
• Yamout B, Alroughani R, Al-Jumah M, et al. Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Curr Med Res Opin 2013;29:611-21
   PubMed Web of Science ®Google Scholar
• Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-68
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Simon JH, Li D, Traboulsse A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. Am J Neuroradiol 2006;27:455-61
   Google Scholar
• Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo – final report. Neurology 1970;20:1-59
   PubMed Web of Science ®Google Scholar
• Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical–immunologic correlations. Neurology 1986;36:238-43
   PubMed Web of Science ®Google Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-16
   PubMed Web of Science ®Google Scholar
• Milanese C, La Mantia L, Salmaggi A, et al. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 1989;29:10-14
   PubMed Web of Science ®Google Scholar
• Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000:CD001331
   PubMedGoogle Scholar
• Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012;12:CD006921
   PubMedGoogle Scholar
• Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J Neurol 2004;251:1329-39
   PubMed Web of Science ®Google Scholar
• Berkovich R FM, Subhani D. Adrenocorticotropic hormone treatment of multiple sclerosis exacerbations. San Diego, CA: Consortium of Multiple Sclerosis Centers, 2012
   Google Scholar
• Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143-9
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86
   PubMed Web of Science ®Google Scholar
• Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009;73:949-53
   PubMed Web of Science ®Google Scholar
• Trebst C, Reising A, Kielstein JT, et al. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108-15
   PubMed Web of Science ®Google Scholar
• Habek M, Barun B, Puretic Z, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial 2010;14:298-302
   PubMed Web of Science ®Google Scholar
• Magana SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68:870-8
   PubMed Web of Science ®Google Scholar
• Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300
   PubMed Web of Science ®Google Scholar
• Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004;10:89-91
   PubMed Web of Science ®Google Scholar
• Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008;15:1163-7
   PubMed Web of Science ®Google Scholar
• Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-5
   PubMed Web of Science ®Google Scholar
• Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 2014;9:e90509
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-82
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72
   PubMed Web of Science ®Google Scholar
• Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010;16:156-65
   PubMed Web of Science ®Google Scholar
• Sombekke MH, Wattjes MP, Balk LJ, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013;80:69-75
   PubMed Web of Science ®Google Scholar
• Mowry EM, Deen S, Malikova I, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400-3
   PubMed Web of Science ®Google Scholar
• Villar LM, Garcia-Barragan N, Sadaba MC, et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008;266:34-7
   PubMed Web of Science ®Google Scholar
• Mitjana R, Tintore M, Rocca MA, et al. Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Mult Scler 2014;20:1471-7
   PubMed Web of Science ®Google Scholar
• Swanton JK, Fernando K, Dalton CM, et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry 2006;77:1070-2
   PubMed Web of Science ®Google Scholar
• Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003;121:944-9
   PubMed Web of Science ®Google Scholar
• Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012;11:157-69
   PubMed Web of Science ®Google Scholar
• Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008:CD005278
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:33-41
   PubMed Web of Science ®Google Scholar
• O'Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler 2009;15:728-34
   PubMed Web of Science ®Google Scholar
• Ruet A, Deloire MS, Ouallet JC, et al. Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult Scler 2011;17:312-18
   PubMed Web of Science ®Google Scholar
• Ruet A, Arrambide G, Brochet B, et al. Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Mult Scler 2014;20:1721-6
   PubMed Web of Science ®Google Scholar
• Miller AWJ, Kappos L, Comi G, et al. TOPIC Main Outcomes: Efficacy and Safety of Once-Daily Oral Teriflunomide in patients with Clinically Isolated Syndrome. Copenhagen, Denmark: ECTRIMS, 2013
   Google Scholar
• Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev 2001:CD002002
   PubMedGoogle Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012;78:1315-22
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing–remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-65
   PubMed Web of Science ®Google Scholar
• Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep 2011;11:492-7
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013;260:2023-32
   PubMed Web of Science ®Google Scholar
• Spelman TBN, Tomic D, Trojano M, et al. Real-world comparative effectiveness of fingolimod and interferon/glatiramer therapies in a switch population using propensity-matched data from MSBase. Copenhagen, Denmark: ECTRIMS, 2013
   Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2013;29:1647-56
   PubMed Web of Science ®Google Scholar
• Lu E, Wang BW, Alwan S, et al. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs 2014;28:89-94
   PubMed Web of Science ®Google Scholar
• Palmer AM. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs 2010;11:1313-23
   PubMed Web of Science ®Google Scholar
• Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012;142:49-56
   PubMed Web of Science ®Google Scholar
• Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
   PubMed Web of Science ®Google Scholar
• Henson LBM, Truffinet P, Kieseier B. Updated Pregnancy Outcomes in Patients and Partners of Patients in the Teriflunomide Clinical Trial Program. Philadelphia, PA: American Academy of Neurology, 2014
   Google Scholar
• Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep 2013;13:394--401
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Fernandez O, Giovannoni G, Fox R, et al. Efficacy of delayed-release dimethyl fumarate for relapsing–remitting multiple sclerosis (RRMS) in ‘non-responders' to prior treatment with interferon beta. Istanbul, Turkey: ENS/EFNS, 2014
   Google Scholar
• Biogen Idec. Safety update with Tecfidera. Available at: http://www.biogenidec.com/therapies_tecfidera.aspx?ID=13012 [Last accessed 8 March 2015]
   Google Scholar
• Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
   PubMed Web of Science ®Google Scholar
• Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;10:CD007621
   PubMed Web of Science ®Google Scholar
• Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012;18:64-71
   PubMed Web of Science ®Google Scholar
• Fernandez O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 2012;259:1814-23
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Quarantelli M, Bonavita S, et al. Natalizumab vs interferon beta 1a in relapsing–remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand 2012;126:306-14
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Bonavita S, Quarantelli M, et al. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci 2013;34:521-8
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Medical information website. Available at: https://medinfo.biogenidec.com/medinfo. Accessed September 2012 to August 30, 2014
   Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
   PubMed Web of Science ®Google Scholar
• Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013;57:141-6
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-12
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2014;21:198-205
   PubMed Web of Science ®Google Scholar
• Fox EJ. Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis. Expert Rev Neurother 2010;10:1789-97
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Comi G. Early treatment. Neurol Sci 2006;27(Suppl 1):S8-12
   PubMed Web of Science ®Google Scholar
• Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013;19:s321-31
   PubMed Web of Science ®Google Scholar
• Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009;25:2459-70
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol 2006;59:344-52
   PubMed Web of Science ®Google Scholar
• Sormani MP, Rio J, Tintore M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605-12
   PubMed Web of Science ®Google Scholar
• Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008;14:1234-41
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40:307-23
   PubMed Web of Science ®Google Scholar
• Dobson R, Rudick RA, Turner B, et al. Assessing treatment response to interferon-beta: is there a role for MRI? Neurology 2014;82:248-54
   PubMed Web of Science ®Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
   PubMed Web of Science ®Google Scholar
• Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a in MS (SPECTRIMS) Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
   PubMed Web of Science ®Google Scholar
• La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012;1:CD005181
   PubMedGoogle Scholar
• Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983;10(Suppl B):3-11
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127
   PubMedGoogle Scholar
• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40
   PubMed Web of Science ®Google Scholar
• Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73-7
   PubMed Web of Science ®Google Scholar
• Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80-3
   PubMed Web of Science ®Google Scholar
• Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10(Suppl 1):S62,discussion 62-4
   Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
   PubMed Web of Science ®Google Scholar
• Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13:1107-17
   PubMed Web of Science ®Google Scholar